Bernd Schollmeier

•Provide board-level strategic counsel to align early-stage oncology, biological, and diagnostics pipelines with global access objectives and government affairs strategies.

•Direct high-stakes landscape research, innovative funding frameworks, and policy risk-mitigation strategies to de-risk commercialization across international markets.

•Advise biopharma clients on global asset valuation, floor price governance, and international reference pricing (IRP) models to protect cross-regional profitability.

Franchise Leadership & Governance: Built and spearheaded the Global Market Access Vaccines franchise from inception. Served as Swiss Board Member and Country Lead, scaling international consultant teams and holding full P&L accountability.

High-Stakes Client Advisory: Directed international market access, floor price governance, and launch sequencing for advanced biologicals, vaccines, and orphan drugs for multinational pharma and biotech clients. Guided investors through 40+ asset due diligence projects.

Combination Vaccine Market Entry: Architected the global access and pricing infrastructure for a breakthrough RSV/hMPV combination vaccine for a top-tier global pharmaceutical leader.

Strategic Asset Indication Pivot: Executed a comprehensive market analysis for a HepB antibody project with the University of Lübeck; strategically shifted clinical focus from a therapeutic approach to a preventive monoclonal antibody, increasing forecasted peak sales from USD 50M to USD 500M.

Payer Governance & Advisory: Frameworked and moderated specialized European RSV Advisory Boards, gathering public health stakeholders, NITAGs, and payers to align regional funding pathways.

Global Market Architecture: Designed endemic market access for a blockbuster Dengue vaccine, structured US health-economic pricing models for a universal Influenza vaccine, and directed UK procurement for travel vaccines.

Industry Thought Leadership: Created and hosted the exclusive educational podcast series "VacciTalks: Vaccine Development from Bench to Patient". Conducted strategic sessions with global pioneers (e.g., Prof. Dr. Joe Schmitt, former Chair of STIKO) to deconstruct the registration-versus-recommendation chasm, cross-functional matrix alignment, and public-private policy collaboration.g.

o Rare Disease & Haematology Market Entry: Developed comprehensive commercial business cases, pricing architecture, and European market entry frameworks for international biotechnology clients launching specialized orphan drugs and high-cost haematology therapies.

o Asset Valuation & Pipeline Optimization: Conducted multi-layered asset valuations, Net Present Value (NPV) analyses, and target product profile (TPP) optimizations for early-stage biological pipelines, enabling biotechs to secure venture funding and strategic partnerships.

o Cross-Border Reference Pricing Architecture: Designed proactive risk-mitigation strategies and global floor price governance frameworks to insulate premium therapeutic assets from European International Reference Pricing (IRP) erosion.

o Value Proposition Refinement: Partnered with executive leadership teams at emerging biotech start-ups to translate early clinical and real-world evidence (RWE) into compelling value propositions tailored to the requirements of European Health Technology Assessment (HTA) bodies.